Business Description
Precision BioSciences Inc
NAICS : 325412
SIC : 2834
ISIN : US74019P2074
Total Employee Number:
66Description
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 16.43 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.15 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -3.06 | |||||
Beneish M-Score | 1044.11 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -32.2 | |||||
3-Year EBITDA Growth Rate | 46.4 | |||||
3-Year EPS without NRI Growth Rate | 40.3 | |||||
3-Year FCF Growth Rate | 32.3 | |||||
3-Year Book Growth Rate | -38.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 14.65 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -27.1 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 62.02 | |||||
9-Day RSI | 67.72 | |||||
14-Day RSI | 66.03 | |||||
3-1 Month Momentum % | -3.3 | |||||
6-1 Month Momentum % | 64.54 | |||||
12-1 Month Momentum % | 33.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.02 | |||||
Quick Ratio | 14.02 | |||||
Cash Ratio | 12.81 | |||||
Days Sales Outstanding | 10.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -86.7 | |||||
Shareholder Yield % | -33.08 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -86.77 | |||||
Net Margin % | -96.73 | |||||
EBITDA Margin % | -89.67 | |||||
FCF Margin % | -131.41 | |||||
OCF Margin % | -130.3 | |||||
ROE % | -80.66 | |||||
ROA % | -34.87 | |||||
ROIC % | -80.5 | |||||
3-Year ROIIC % | -18.93 | |||||
ROC (Joel Greenblatt) % | -585.14 | |||||
ROCE % | -37.98 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3.92 | |||||
PB Ratio | 2.9 | |||||
Price-to-Tangible-Book | 2.94 | |||||
EV-to-EBIT | -3.04 | |||||
EV-to-EBITDA | -3.24 | |||||
EV-to-Forward-EBITDA | -2.54 | |||||
EV-to-Revenue | 2.91 | |||||
EV-to-Forward-Revenue | 6.14 | |||||
EV-to-FCF | -2.21 | |||||
Price-to-GF-Value | 4.79 | |||||
| Price-to-Net-Current-Asset-Value | 5.51 | |||||
| Price-to-Net-Cash | 7.18 | |||||
Earnings Yield (Greenblatt) % | -32.89 | |||||
FCF Yield % | -26.21 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DTIL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Precision BioSciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 45.073 | ||
| EPS (TTM) ($) | -3.67 | ||
| Beta | 2.0542 | ||
| 3-Year Sharpe Ratio | 0.06 | ||
| 3-Year Sortino Ratio | 0.09 | ||
| Volatility % | 78.64 | ||
| 14-Day RSI | 66.03 | ||
| 14-Day ATR ($) | 0.626034 | ||
| 20-Day SMA ($) | 7.47225 | ||
| 12-1 Month Momentum % | 33.54 | ||
| 52-Week Range ($) | 3.53 - 9.62 | ||
| Shares Outstanding (Mil) | 25.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Precision BioSciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Precision BioSciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-03 | In 115 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 27 days | ||
| Guidance call for 2026 | 2026-05-27 08:00 | 7.58 (+3.13%) | ||
| General meeting for 2026 | 2026-05-21 10:00 | 7.18 (+3.31%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 7.63 (+5.10%) | ||
| Guidance call for 2026 | 2026-04-14 09:30 | 7.13 (+7.70%) | ||
| Annual report for 2025 | 2026-03-12 | 5.06 (-5.07%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 5.06 (-5.07%) | ||
| Sidoti Events | 2025-12-11 09:15 | 5.01 (+3.09%) | ||
| Third quarter earnings results for 2025 | 2025-11-03 | 8.16 (-5.56%) |
Show
Entries
Precision BioSciences Inc Frequently Asked Questions
What is Precision BioSciences Inc(DTIL)'s stock price today?
The current price of DTIL is $8.77. The 52 week high of DTIL is $9.62 and 52 week low is $3.53.
When is next earnings date of Precision BioSciences Inc(DTIL)?
The next earnings date of Precision BioSciences Inc(DTIL) is 2026-08-07 Est..
Does Precision BioSciences Inc(DTIL) pay dividends? If so, how much?
Precision BioSciences Inc(DTIL) does not pay dividend.
Guru Commentaries on NAS:DTIL
No articles.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers